Last reviewed 2026-04-19 · How we verify

Flupentixole

Flupentixole is a dopamine D2 receptor antagonist that reduces psychotic symptoms by blocking dopamine receptors in the brain.

Flupentixole is an antipsychotic medication primarily used in the treatment of schizophrenia and other psychotic disorders. Developed by the Technical University of Munich, it operates as a dopamine D2 receptor antagonist, which helps to reduce symptoms such as delusions and hallucinations. Despite its efficacy, flupentixole has not received FDA approval, limiting its use primarily to European markets. Common side effects include extrapyramidal symptoms, sedation, and weight gain. The drug's safety profile includes warnings for patients with cardiovascular conditions and those at risk of tardive dyskinesia.

At a glance

Mechanism of action

By blocking dopamine D2 receptors, flupentixole decreases the activity of dopaminergic pathways, which are overactive in conditions like schizophrenia.

Approved indications

Boxed warnings

• Increased risk of cardiovascular events
• Risk of tardive dyskinesia

Common side effects

• Extrapyramidal symptoms
• Sedation
• Weight gain

Drug interactions

• CYP2D6 inhibitors
• Anticholinergics
• Benzodiazepines

Key clinical trials

• Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
• Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Flupentixole CI brief — competitive landscape report
• Flupentixole updates RSS · CI watch RSS
• Technical University of Munich portfolio CI